Management of patients at risk of bisphosphonate osteonecrosis in maxillofacial surgery units in the UK

Surgeon

Volumn 7, Issue 1, 2009, Pages 18-23

  McLeod, Niall M H ^a,b   Davies, B J B ^a   Brennan, P A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Bisphosphonate; Oral surgery; Osteonecrosis

Indexed keywords

EID: 60249092718     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(09)80062-0     Document Type: Article

References (28)

1. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (Bis-Phossy Jaw): Is this phossy jaw of the 21St Century? J Oral Maxillofac Surg 2005; 63: 682-89
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [letter] J Oral Maxillofac Surg 2003; 61: 115-18
3. Woo S, Hellstein JW, Kalmar JR. Systematic review. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144: 753-61
4. American Dental Association council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy. J Am Dent Assoc 2006; 137(8): 1144-50
5. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaws. Australian Family Physician 2006; 35(10): 801-3
6. Fleisch H. Bisphosphonates: Mechanisms of action. Endoc Rev 2002; 19(1): 80-100
7. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999, 2(suppl):s66-s80
8. Palomo L, Bissada N, Liu J. Bisphisphonate therapy for bone loss in patients with osteoporosis and periodontal disease: Clinical perspectives and review of the literature. Quintessence Int 2006; 37(2): 103-7
9. Santini D, Vespasiani Gentilucci U, Vincenzi B et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14: 1468-76
10. Wood J, Bonjean K, Reutz S et al. Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacology and Experimental Therapeutics 2002; 302(3): 1055-61
11. American Association of Oral & Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. 2006.http:/ /www.aaoms.org/docs/position_papers/osteonecrosis.pdf
12. Chiandusi S, Biasotto M, Dore F et al. Clinical and diagnostic imaging of bisphosphonate - associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006; 35: 236-43
13. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61:1104-7
14. Pancholi M, Edwards A, Langton S. Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour. Br Dent J 2007;203(2):87-89
15. Srinivasan D, Shetty S, Ashworth D, Grew N, Millar B. Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws. Br Dent J 2007;203 (2):91-92
16. Maiden NJ, Pai AY. Oral Bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 2007; 203(2):93-97
17. www.mhra.gov.uk, accessed January 2007.
18. Review Available at: www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4095B2_03_04-FDA-TAB3.pdf - 03-02-2005 - Accessed January 2007
19. British Medical Association, Royal Pharmaceutical society of Great Britain. BNF 52, Section 6.6.2 Bisphosphonates. Sep 2006
20. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006:102(4): 433-41.
21. Ensrud KE, Barrett-Connor EL, Schwartz A et al. 2004 Randomized trial of effect of aledronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long term extension. J Bone Miner Res 2004; 19; 1259-69
22. Rodan G, Reszka A, Golub E et al. Bone safety of long term bisphosphonate treatment. Curr Med Res Opin 2004; 20(8): 1291-1300
23. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaws in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24(6): 945-52
24. Cheng A, Mavrokokki A, Carter G et al. The dental implication of bisphosphonates and bone disease. Aust Dent J 2005; 50 (Suppl 2): S4-13
25. Lacy MQ, Dispenzieri A, Gertz MA et al. Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. Mayo Clin Proc 2006; 81(8): 1047-53
26. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Res Ther 2006; 8: 219
27. Caso A, Hung L, Beirne OR. Prevention of alveolar osteitis with Chlorhexidene; a meta-analytic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 155-59
28. Laskin DM. The use of prophylactic antibiotics in the prevention of postoperative infections. Oral Maxillofac Surg Clin N Am 2003; 15; 155-60